论文部分内容阅读
目的研究格列齐特结合舒洛地特治疗对糖尿病肾病患者血管内皮细胞生长因子的影响。方法随机选取2012年4月—2013年6月我院收治的糖尿病肾病患者120例,将其随机分为对照组和观察组各60例,对照组给予舒洛地特治疗,观察组在此基础上同时服用格列齐特,于治疗后第四周、第八周,测定患者体内血管内皮细胞生长因子(VEGF)。结果使用格列齐特结合舒洛地特治疗后,患者体内VEGF水平显著下降(tc=11.051,td=17.176,P<0.05)。结论格列齐特结合舒洛地特治疗可有效降低患者体内血管内皮细胞生长因子的表达。
Objective To study the effect of gliclazide combined with sulodentia on vascular endothelial growth factor in patients with diabetic nephropathy. Methods A total of 120 diabetic nephropathy patients admitted to our hospital from April 2012 to June 2013 were selected randomly and randomly divided into control and observation groups of 60 cases and control group treated with sulodentia. Gliclazide at the same time, in the fourth week after treatment, the eighth week, the determination of the patient’s vascular endothelial growth factor (VEGF). Results In patients treated with gliclazide and sulodexide, the level of VEGF was significantly decreased (tc = 11.051, td = 17.176, P <0.05). Conclusion Gliclazide combined with sulodexide can effectively reduce the expression of VEGF in patients.